Elevated resting energy expenditure among HIV-seropositive persons receiving highly active antiretroviral therapy

AIDS

Volumn 13, Issue 11, 1999, Pages 1351-1357

  Shevitz, Abby H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; HIV; Metabolism; Protease inhibitors; Resting energy expenditure; Viral load; Wasting; Weight loss

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ADULT; AGED; ARTICLE; BODY MASS; ENERGY EXPENDITURE; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METABOLIC RATE; NUTRITION; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; BASAL METABOLISM; BODY COMPOSITION; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 0032859850     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199907300-00012     Document Type: Article

References (61)

1. Hommes MJ, Romijn JA, Godfried MH, et al. Increased resting energy expenditure in human immunodeficiency virus-infected men. Metabolism 1990, 39:1186-90.
2. Crunfeld C, Pang M, Shimizu L, et al. Resting energy expenditure, caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutr 1992, 55:455-60.
3. Hommes MJT,. Romijn JA, Endert E, Sauerwein HP. Resting energy expendiure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. Am J Clin Vutr 1991, 54, 311-15.
4. Melchior JC, Raguin G, Boulier A, et al. Resting energy expenditure in human immunodeficiency virus-infected patients: comparison between patients with and without secondary infections. Am J Clin Nutr 1993, 57:614-19.
5. Melchior JC, Salmon D, Rigaud D, et al. Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 1991, 53, 437-41.
6. Suttmann U, Ockenga J, Hoogestraat L, et al. Resting energy expenditure and weight loss in human immunodeficiency virus-infected patients. Metabolism 1993, 42:1173-9.
7. Macallan DC, Noble C, Baldwin C, et al. Energy expenditure and wasting in human immunodeficiency virus Infection. N EnglJ Med 1995, 333:83-8.
8. Kotler DP, Tierney AR, Brenner SK, et al. Preservation of shortterm energy balance in clinically stable patients with AIDS. Am J Clin Nutr 1990, 51:7-13.
9. NIH Panel to Define Principles of Therapy of HIV Infection. Report of the NIH panel to define principles of therapy of HIV infection: Ann Intern Med 1998, 128:1057-78.
10. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 1998:280:78-86.
11. O'Brien TR, Blattner VVA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. JAMA 1996, 276:105-10.
12. O'Brien VVA, Hartigan PM, Martin D, et al. Changes in plasma HIV RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. NEngl] Med 1996, 334:426-31.
13. Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologie and immunologie markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. N Engl J Med 1996, 335:1091-8.
14. Perelson AS, Neumann AU, Markowitz.M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rale, infected cell life-span and viral generation time. Science 1996, 271:1582-6.
15. Raboud JM, Montaner JS, Rae S, et al. Issues in the design of trials of therapies for subjects with human immunodeficeincy virus infection that use plasma RNA level as an outcome. J Infect Dis 1997, 175:576-82.
16. Kempf D, Molla A, Sun E, et al. The duration of viral suppression is predicted by viral load during protease inhibitor therapy. Fourth Conference on Retroviruses and Opportunistic Infections. Washington, DC, January 1997 (Abstract 603).
17. DeCruttola V, for the ACTC Cross Protocol Study Croup. Prognostic value of CD4 counts and plasma HIV RNA: an ACTG cross protocol analysis. In: Proceedings of the Public Meeting of the NIH Panel to define Principles of Therapy of HIV infection. Washington, DC: Office of AIDS Reserach, NIH; 1998.
18. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus typé 1 infection. Nature 1995, 373:117-22.
19. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-6.
20. Rivera S, Briggs W, Qian D, Sattler FR. Levels of HIV RNA are quantitatively related to prior weight loss in HIV-associated wasting. J Acquir Immune Defic Syndr Hum Retrovirol 1998, 17:411-18.
21. Mulligan K, Tai WV, and Schambelan M. Energy expenditure in human immunodeficiency virus infection. N Engl J Med 1997, 336: 70-1.
22. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. Lancet 1998, 351:543-9.
23. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus Infection. N Engl J Med 1998, 338:853-60.
24. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997, 337:725-33.
25. + persons receiving protease inhibitor therapy: incidence, risks and endocrinologie evaluation. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 408].
26. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998, 351:867-70.
27. Carr A, Samaras K, Burton S, et aJ. A syndrome of peripheral lipodyslrophy, hyperlipidemia and insulin resistance due to HIV protease inhibitors. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 (abstract 410].
28. Roth VR, Angel JB, Kravcik S. Development of a cervical fat pad following treatment with HIV-1 protease inhibitors. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 411].
29. Mann M, Piazza-Hepp T, Koller E, Cibert C. Abnormal fat distribution in AIDS patients following protease inhibitor therapy: FDA Summary. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 412].
30. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998, 351:871-5.
31. Visnegarwala F, Krause KL, Musher DM. Severe diabetes associated with protease inhibitor therapy. Ann Intern Med 1997, 127:957.
32. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of prolease inhibitor. Ann Inter Med 1997, 127:957.
33. Dube MP, Johnson DL, Currier )S, Leedom JM. Protease inhibitor-associated hyperglycaemia. lancet 1997, 350:713-14.
34. Mulligan K, Tai VW, Algren H, et al. Evidence of unique metabolic effects of protease inhibitors. Fifth Conference on Retroviruses and Opportunistic Infections. Chicago, February 1998 [abstract 414].
35. Larson TB, Brunner SR. The effect of protease inhibitors on the nutritional health of HIV infected adults. XII International Conference on AIDS. Geneva, June1998 [abstract 42 346].
36. Bozzette SA, Hays RD, Berry SH, Kanouse D, Wu AW. Derivation and properties of a brief health status assessment instrument for use in HIV disease. J Acquit Immune Defic Syndr Hum Relrovirol 1995, 8:253-6.
37. Centers for Disease Control. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MJUVVR 1992, 41:RR-17.
38. Weir JB. New method for calculating metabolic rate with special reference to protein metabolism J Physiol 1949, 109:1-9.
39. Durnin JVCA, Womersley J. Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged 16 to 72 years. Br J Nutr 1974, 32:77-97.
40. Lohman TC, Roche AF, Martorell R, eds. Anthropometrie Standardization Reference Manual. Champaign, IL: Human Kinetics Books; 1998.
41. NIH Technology Assessment Statement. Bioelectrical impedance analysis in body composition measurement: National Institute of Health Technology Assessment Conference statement. Am I Clin Nulr 1996, 64(Suppl):S524-32.
42. Lukaski HC. Use of bioelectrical impedance analysis to assess human body composition: a review. In: Livingston GE, ed. Nutritional Status Assessment of the Individual. Trumbull, CT: Food & Nutrition Press; 1989:189-204.
43. Zeger SL, Liang K. Longitudinal data analysis for discrete and continuous outcomes. Biometrics 1986, 42:121-30.
44. Harris JA, Benedict FG. A Biometrie Study of Basal Metabolism in Man. (Publication No. 279). Washington DC: Carnegie Institute of Washington; 1919.
45. Durrleman S, Simon R. Flexible regression models with cubic splines. Sial Med 1989, 8:551-61.
46. Crunfeld C, Feingold KR. Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl l Med 1992,327:329-37.
47. Crunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am y Med 1991, 90:154-62.
48. Suttmann U, Selberg O, Gallati H, et aJ. Tumour necrosis factor receptor levels arc linked to the acute phase response and malnutrition in human immunodeficiency-virus-infected patients. Clin Sei 1994, 86:461-7.
49. Roubenoff R, Skolnik P, Knox T, et al. Determinants of metabolic rate and body composition in adults with HIV infection. XI International Conference on AIDS. Vancouver, July 1996: [abstract Mo. B. 1393].
50. Macallan DC, McNurlan MA, Milne E, et al. Whole body protein turnover from leucine kinetics and the response to nutrition in human immunodeficiency virus infection. Am 1 Clin Nutr1995, 61:818-26.
51. Godfried MH, Romign J, van der Poll T, et al. Soluble receptors for tumor necrosis factors are markers for clinical course but not for major metabolic changes in human immunodeficiency virus infection. Metabolism 1995, 44:1564-9.
52. Roubenoff R, Roubenoff RA, Cannon JG, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism and loss of fat-free mass in chronic inflammation, y Clin Invest 1994, 93: 2379-86.
53. Cavert W., Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997, 276:960-4.
54. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologie correlates of treatment failure. Proc Nail AcadSci, USA 1997, 94:12574-9.
55. Nair KS, Halliday D, Garrow JS. Increased energy expenditure in poorly controlled type 1 (insulin-dependent) diabetic patients. Diabetologia 1984, 27:13-16.
56. Nair KS, Webster J, Garrow JS. Effect of impaired glucose tolerance and type II diabetes on resting metabolic rate and thermic response to a glucose meal in obese women. Metabolism 1986,35:640-4.
57. Gougeon R. Thermic and metabolic responses to oral glucose in obese subjects with non-insulin-dependent diabetes mellitus treated with insulin or a very-low-energy diet. Am 1 Clin Nutr 1996, 64:78-86.
58. Poehlman E, Gardner A, Coran M. Influence of endurance training on energy intake, norepinephrine kinetics, and metabolic rate in older individuals. Metabolism 1992, 41:941-8.
59. Broader C, Burrhus K, Svanevik L, Wilmore J. The effects of either high-intensity resistance or endurance training on resting metabolic rate. Am ; Clin Nutr 1992, 55:801-10.
60. Wilmore J, Stanforth P, Hudspeth L, et al. Alterations in resting metabolic rate as a consequence of 20 weeks of endurance training: the HERITAGE Family Study. Am ; Clin Nulr 1998, 68:66-71.
61. Meredith CN, Frontera VVR, Fisher EC, et al. Peripheral effects of endurance training in young and old subjects. J Appl Physiol 1989, 66:2844-9.